Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa
October 06, 2020 07:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio to Participate in Upcoming October Investor Conferences
September 25, 2020 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
September 17, 2020 07:00 ET
|
Passage Bio
Data Show Single Injection of AAV-Granulin Gene Therapy into Central Nervous System Reverses Frontotemporal Dementia Pathology Caused by Granulin Mutations and is Well Tolerated Study Conducted by...
Passage Bio to Participate in Citi’s 15th Annual BioPharma Virtual Conference
September 03, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 13, 2020 07:00 ET
|
Passage Bio
– Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery device – – Anticipate dosing first patient in PBGM01 Phase 1/2 trial in...
Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
August 07, 2020 16:01 ET
|
Passage Bio
PHILADELPHIA, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Added to Russell 2000 Index
June 26, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, June 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference
June 04, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, June 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis
May 21, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, May 21, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system...
Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
May 12, 2020 17:00 ET
|
Passage Bio
– Preclinical data from University of Pennsylvania’s Gene Therapy Program demonstrate single injection of AAVhu68 carrying a functional GALC gene resulted in normalization of GALC enzyme activity and...